Cytochrome p450 enzymes and cardiovascular disease

Canadian Journal of Physiology and Pharmacology

Volumn 82, Issue 12, 2004, Pages 1053-1060

  Hunter, Arwen L ^a   Cruz, Rani P ^a   Cheyne, Bo M ^a   McManus, Bruce M ^a   Granville, David J ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Atherosclerosis; Cytochrome p450; Endothelial cell; Heart; Ischemia; Reactive oxygen species

Indexed keywords

11,12 EPOXY 5,8,14 ICOSATRIENOIC ACID; 17 OCTADECYNOIC ACID; 20 HYDROXYICOSATETRAENOIC ACID; 4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; 6 (2 PROPARGLYOXYPHENYL)HEXANAMIDE; ACETALDEHYDE; AMIODARONE; ANTIARRHYTHMIC AGENT; ANTIHYPERTENSIVE AGENT; CANDESARTAN; CARDIOVASCULAR AGENT; CHLORAMPHENICOL; CIMETIDINE; CYTOCHROME P450; CYTOCHROME P450 2C9; CYTOCHROME P450 INHIBITOR; DEETHYLAMIODARONE; DEXTROMETHORPHAN; ENDOTHELIUM DERIVED HYPERPOLARIZING FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; EPOXYICOSATRIENOIC ACID; HYDROXYICOSATETRAENOIC ACID; IRBESARTAN; PHENYTOIN; PROPAFENONE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; SULFAPHENAZOLE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASODILATOR AGENT; WARFARIN;

ANGIOGENESIS; ATHEROSCLEROSIS; CARDIOMYOPATHY; CARDIOVASCULAR DISEASE; CONGESTIVE HEART FAILURE; DISEASE COURSE; DRUG INHIBITION; DRUG METABOLISM; DRUG SAFETY; ENDOTHELIUM CELL; ENZYME MECHANISM; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART MUSCLE ISCHEMIA; HOMEOSTASIS; HUMAN; HYPERTENSION; NONHUMAN; OXIDATION; PATHOGENESIS; PEROXIDATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REDUCTION; REVIEW; SIDE EFFECT; VASODILATATION;

ANIMALS; CARDIOVASCULAR DISEASES; CYTOCHROME P-450 ENZYME SYSTEM; HOMEOSTASIS; HUMANS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 14844330053     PISSN: 00084212     EISSN: None     Source Type: Journal    
DOI: 10.1139/y04-118     Document Type: Review

References (56)

1. Aberle, N.S., II, and Ren, J. 2003. Short-term acetaldehyde exposure depresses ventricular myocyte contraction: role of cytochrome P450 oxidase, xanthine oxidase, and lipid peroxidation. Alcohol. Clin. Exp. Res. 27: 577-583.
2. Busse, R., and Fleming, I. 1998. Regulation of NO synthesis in endothelial cells. Kidney Blood Press. Res. 21: 264-266.
3. Campbell, W.B., Gebremedhin, D., Pratt, P.F., and Harder, D.R. 1996. Identification of epoxyeicosatrienoic acids as endothelium-derived hyperpolarizing factors. Circ. Res. 78: 415-423.
4. Chow, M.S., White, C.M., Lau, C.P., Fan, C., and Tang, M.O. 2001. Evaluation of CYP2D6 oxidation of dextromethorphan and propafenone in a Chinese population with atrial fibrillation. J. Clin. Pharmacol. 41: 92-96.
5. Dai, D., Zeldin, D.C., Blaisdell, J.A., Chanas, B., Coulter, S.J., Ghanayem, B.I., and Goldstein, J.A. 2001. Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid. Pharmacogenetics, 11: 597-607.
6. Ding, X., and Kaminsky, L.S. 2003. Human extrahepatic cytochromes P450: function in xenobiotic metabolism and tissue-selective chemical toxicity in the respiratory and gastrointestinal tracts. Annu. Rev. Pharmacol. Toxicol. 43: 149-173.
7. Fichtlscherer, S., Dimmeler, S., Breuer, S., Busse, R., Zeiher, A.M., and Fleming, I. 2003. Inhibition of cytochrome P450 2C9 improves endothelium-dependent, nitric oxide-mediated vasodilatation in patients with coronary artery disease. Circulation, 1619: 332-339.
8. Fisslthaler, B., Popp, R., Kiss, L., Potente, M., Harder, D.R., Fleming, I., and Busse, R. 1999. Cytochrome P450 2C is an EDHF synthase in coronary arteries. Nature (London), 401: 493-497.
9. Fleming, I. 2001. Cytochrome p450 and vascular homeostasis. Circ. Res. 89: 753-762.
10. Fleming, I., Michaelis, U.R., Bredenkotter, D., Fisslthaler, B., Dehghani, F., Brandes, R.P., and Busse, R. 2001. Endothelium-derived hyperpolarizing factor synthase (cytochrome P450 2C9) is a functionally significant source of reactive oxygen species in coronary arteries. Circ. Res. 88: 44-51.
11. Frye, R.F., Schneider, V.M., Frye, C.S., and Feldman, A.M. 2002. Plasma levels of TNF-alpha and IL-6 are inversely related to cytochrome P450-dependent drug metabolism in patients with congestive heart failure. J. Cardiac Failure, 8: 315-319.
12. Gibbs, R.A., Weinstock, G.M., Metzker, M.L., Muzny, D.M., Sodergren, E.J., Scherer, S. et al. 2004. Genome sequence of the brown Norway rat yields insights into mammalian evolution. Nature (London), 428: 493-521.
13. Granville, D.J., Tashakkor, B., Takeuchi, C., Gustafsson, A.B., Huang, C., Sayen, M.R. et al. 2004. Reduction of ischemia and reperfusion-induced myocardial damage by cytochrome P450 inhibitors. Proc. Natl. Acad. Sci. USA, 101: 1321-1326.
14. Guengerich, F.P. 2002. Cytochrome P450 enzymes in the generation of commercial products. Nat. Rev. Drug Discov. 1: 359-366.
15. Hallberg, P., Karlsson, J., Kurland, L., Lind, L., Kahan, T., Malmqvist, K. et al. 2002. The CYP2C9 genotype predicts the blood pressure response to irbesartan: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs. Atenolol (SILVHIA) trial. J. Hypertens. 20: 2089-2093.
16. Holla, V.R., Adas, F., Imig, J.D., Zhao, X., Price, E., Jr., Olsen, N. et al. 2001. Alterations in the regulation of androgen-sensitive Cyp 4a monooxygenases cause hypertension. Proc. Natl. Acad. Sci. USA, 98: 5211-5216.
17. Idle, J.R. 2000. The heart of psychotropic drug therapy. Lancet, 355: 1824-1825.
18. Imig, J.D., Falck, J.R., Wei, S., and Capdevila, J.H. 2001. Epoxygenase metabolites contribute to nitric oxide-independent afferent arteriolar vasodilation in response to bradykinin. J. Vasc. Res. 38: 247-255.
19. Jiang, M., Mezentsev, A., Kemp, R., Byun, K., Falck, J.R., Miano, J.M. et al. 2004. Smooth musclespecific expression of CYP4A1 induces endothelial sprouting in renal arterial microvessels. Circ. Res. 94: 167-174.
20. Kaduce, T.L., Fang, X., Harmon, S.D., Oltman, C.L., Dellsperger, K.C., Teesch, L.M. et al. 2004. 20-Hydroxyeicosatetraenoic acid (20-HETE) metabolism in coronary endothelial cells. J. Biol. Chem. 279: 2648-2656.
21. Karara, A., Dishman, E., Falck, J.R., and Capdevila, J.H. 1991. Endogenous epoxyeicosatrienoyl-phospholipids. A novel class of cellular glycerolipids containing epoxidized arachidonate moieties. J. Biol. Chem. 266: 7561-7569.
22. Lander, E.S., Linton, L.M., Birren, B., Nusbaum, C., Zody, M.C., Baldwin, J. et al. 2001. Initial sequencing and analysis of the human genome. Nature (London), 409: 860-921.
23. + channels in coronary smooth muscle through a guanine nucleotide binding protein. Circ. Res. 80: 877-884.
24. Malhotra, R.W.G., and Lilly, L.S. 2003. Hypertension. In Pathophysiology of heart disease: a collabortive project of medical students and faculty. Edited by L. LS. Lippincott Williams & Wilkins, Baltimore, Md. pp. 289-310.
25. McGiff, J.C., and Quilley, J. 2001. 20-Hydroxyeicosatetraenoic acid and epoxyeicosatrienoic acids and blood pressure. Curr. Opin. Nephrol. Hypertens. 10: 231-237.
26. Medhora, M., Daniels, J., Mundey, K., Fisslthaler, B., Busse, R., Jacobs, E.R., and Harder, D.R. 2003. Epoxygenase-driven angiogenesis in human lung microvascular endothelial cells. Am. J. Physiol. Heart Circ. Physiol. 284: H215-H224.
27. Messer-Letienne, I., Bernard, N., Roman, R.J., Sassard, J., and Benzoni, D. 1999. 20-Hydroxyeicosatetraenoic acid and renal function in Lyon hypertensive rats. Eur. J. Pharmacol. 378: 291-297.
28. Michaelis, U.R., Fisslthaler, B., Medhora, M., Harder, D., Fleming, I., and Busse, R. 2003. Cytochrome P450 2C9-derived epoxyeicosatrienoic acids induce angiogenesis via cross-talk with the epidermal growth factor receptor (EGFR). FASEB J. 17: 770-772.
29. Morel, Y., and Barouki, R. 1998. Down-regulation of cytochrome P450 1A1 gene promoter by oxidative stress. J. Biol. Chem. 273: 26 969-26 976.
30. Morgan, E.T., Sewer, M.B., Iber, H., Gonzalez, F.J., Lee, Y.H., Tukey, R.H. et al. 1998. Physiological and pathophysiological regulation of cytochrome P450. Drug Metab. Dispos. 26: 1232-1240.
31. Morgan, E.T., Li-Masters, T., and Cheng, P.Y. 2002. Mechanisms of cytochrome P450 regulation by inflammatory mediators. Toxicology, 181-182: 207-210.
32. Nadeau, J.H., Balling, R., Barsh, G., Beier, D., Brown, S.D., Bucan, M. et al. 2001. Sequence interpretation. Functional annotation of mouse genome sequences. Science (Wash., DC), 291: 1251-1255.
33. Naganuma, M., Shiga, T., Nishikata, K., Tsuchiya, T., Kasanuki, H., and Fujii, E. 2001. Role of desethylamiodarone in the anticoagulant effect of concurrent amiodarone and warfarin therapy. J. Cardiovasc. Pharmacol. Ther. 6: 363-367.
34. Pratt, P.F., Falck, J.R., Reddy, K.M., Kurian, J.B., and Campbell, W.B. 1998. 20-HETE relaxes bovine coronary arteries through the release of prostacyclin. Hypertension, 31: 237-241.
35. Rendic, S., and Di Carlo, F.J. 1997. Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors. Drug Metab. Rev. 29: 413-580.
36. Roman, R.J. 2002. P-450 metabolites of arachidonic acid in the control of cardiovascular function. Physiol. Rev. 82: 131-185.
37. Satoh, M., Nakamura, M., Saitoh, H., Satoh, H., Akatsu, T., Iwasaka, J. et al. 2002. Aldosterone synthase (CYP11B2) expression and myocardial fibrosis in the failing human heart. Clin. Sci. (London) 102: 381-386.
38. Shatara, R.K., Quest, D.W., and Wilson, T.W. 2000. Fenofibrate lowers blood pressure in two genetic models of hypertension. Can. J. Physiol. Pharmacol. 78: 367-371.
39. Shi, M.M. 2001. Enabling large-scale pharmacogenetic studies by high-throughput mutation detection and genotyping technologies. Clin. Chem. 47: 164-172.
40. Silvestre, J.S., Robert, V., Heymes, C., Aupetit-Faisant, B., Mouas, C., Moalic, J.M. et al. 1998. Myocardial production of aldosterone and corticosterone in the rat. Physiological regulation. J. Biol. Chem. 273: 4883-4891.
41. Stella, P., Bigatti, G., Tizzoni, L., Barlassina, C., Lanzani, C., Bianchi, G., and Cusi, D. 2004. Association between aldosterone synthase (CYP11B2) polymorphism and left ventricular mass in human essential hypertension. J. Am. Coll. Cardiol. 43: 265-270.
42. Takai, E., Akita, H., Kanazawa, K., Shiga, N., Terashima, M., Matsuda, Y. et al. 2002. Association between aldosterone synthase (CYP11B2) gene polymorphism and left ventricular volume in patients with dilated cardiomyopathy. Heart, 88: 649-650.
43. Thum, T., and Borlak, J. 2002. Testosterone, cytochrome P450, and cardiac hypertrophy. FASEB J. 16: 1537-1549.
44. Thum, T., and Borlak, J. 2004. Mechanistic role of cytochrome P450 monooxygenases in oxidized low-density lipoprotein-induced vascular injury: therapy through LOX-1 receptor antagonism? Circ. Res. 94: e1-e13.
45. Uchida, S., Watanabe, H., Nishio, S., Hashimoto, H., Yamazaki, K., Hayashi, H., and Ohashi, K. 2003. Altered pharmacokinetics and excessive hypotensive effect of candesartan in a patient with the CYP2C91/3 genotype. Clin. Pharmacol. Ther. 74: 505-508.
46. VanRollins, M., Kaduce, T.L., Fang, X., Knapp, H.R., and Spector, A.A. 1996. Arachidonic acid diols produced by cytochrome P-450 monooxygenases are incorporated into phospholipids of vascular endothelial cells. J. Biol. Chem. 271: 14 001-14 009.
47. Visser, L.E., van Vliet, M., van Schaik, R.H., Kasbergen, A.A., De Smet, P.A., Vulto, A.G. et al. 2004. The risk of over-anticoagulation in patients with cytochrome P450 CYP2C9*2 or CYP2C9*3 alleles on acenocoumarol or phenprocoumon. Pharmacogenetics, 14: 27-33.
48. Wang, J.F., Yang, Y., Sullivan, M.F., Min, J., Cai, J., Zeldin, D.C. et al. 2002. Induction of cardiac cytochrome p450 in cocaine-treated mice. Exp. Biol. Med. (Maywood), 227: 182-188.
49. Wang, X.L., Raveendran, M., and Wang, J. 2003. Genetic influence on cigarette-induced cardiovascular disease. Prog. Cardiovasc. Dis. 45: 361-382.
50. Weiner, P., Waizman, J., Weiner, M., Rabner, M., Magadle, R., and Zamir, D. 2000. Smoking and first acute myocardial infarction: age, mortality and smoking cessation rate. Isr. Med. Assoc. J. 2: 446-449.
51. Wu, S., Moomaw, C.R., Tomer, K.B., Falck, J.R., and Zeldin, D.C. 1996. Molecular cloning and expression of CYP2J2, a human cytochrome P450 arachidonic acid epoxygenase highly expressed in heart. J. Biol. Chem. 271: 3460-3468.
52. Yamreudeewong, W., DeBisschop, M., Martin, L.G., and Lower, D.L. 2003. Potentially significant drug interactions of class III antiarrhythmic drugs. Drug Saf. 26: 421-438.
53. Yasar, U., Bennet, A.M., Eliasson, E., Lundgren, S., Wiman, B., De Faire, U., and Rane, A. 2003. Allelic variants of cytochromes P450 2C modify the risk for acute myocardial infarction. Pharmacogenetics, 13: 715-720.
54. Young, M.J., Clyne, C.D., Cole, T.J., and Funder, J.W. 2001. Cardiac steroidogenesis in the normal and failing heart. J. Clin. Endocrinol. Metab. 86: 5121-5126.
55. Zhang, Y., Oltman, C.L., Lu, T., Lee, H.C., Dellsperger, K.C., and VanRollins, M. 2001. EET homologs potently dilate coronary microvessels and activate BK(Ca) channels. Am. J. Physiol. Heart Circ. Physiol. 280: H2430-H2440.
56. Zhu, G.J., Yu, Y.N., Li, X., and Qian, Y.L. 2002. Cloning of cytochrome P-450 2C9 cDNA from human liver and its expression in CHL cells. World J. Gastroenterol. 8: 318-322.